CollPlant Biotechnologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by CollPlant Biotechnologies Ltd. on September 21, 2020, covering the month of September 2020. The filing incorporates by reference a press release announcing a strategic expansion of the company's collaboration with United Therapeutics Corporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate development announcement rather than financial performance data.
Material Changes
The primary material change disclosed is the exercise of an option by United Therapeutics to expand their existing collaboration with CollPlant. The expanded scope now includes the 3D bioprinting of human kidneys for transplant purposes.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release but does not detail specific financial guidance or numerical outlooks within the text provided. The document notes that the press release is incorporated into the company's Registration Statements on Form S-8 and Form F-3.
Key Facts for Investor Verification
- CollPlant and United Therapeutics have expanded their collaboration to include 3D bioprinting of human kidneys.
- The expansion was triggered by the exercise of an option by United Therapeutics.
- The press release is dated September 21, 2020, and is attached as Exhibit 99.1.
- No financial performance metrics are included in this specific filing.